ANAlyzeR™ ANA, IFA with Reflex Titer/Pattern, Systemic Autoimmune Panel 1

Antinuclear antibodies are immunoglobulins directed against nuclear and cytoplasmic constituents. Indirect immunofluorescence on HEp-2 cells detects the full spectrum of ANA reactivity, including those to extractable nuclear antigens, dsDNA, centromere, and other intracellular targets. A positive screen reflects the presence of circulating autoantibodies but does not, on its own, establish a diagnosis — healthy individuals, particularly women and older adults, can have low-titre ANA without disease.

The ANA screen by IFA is the recommended first test in suspected systemic autoimmune rheumatic disease. It has high sensitivity for SLE (>95%) and is frequently positive in systemic sclerosis, Sjögren syndrome, inflammatory myositis, and mixed connective-tissue disease. A negative ANA virtually excludes SLE, though drug-induced lupus can occasionally be ANA-negative. Positive results trigger reflex testing to determine titre, pattern, and specific antibody identity.

The titre represents the highest serum dilution at which nuclear fluorescence remains detectable on HEp-2 substrate. It reflects antibody concentration and, indirectly, the intensity of the autoimmune response. Higher titres generally correlate with greater likelihood of systemic autoimmune disease, though overlap with healthy populations exists, particularly at titres of 1:40 to 1:80.

Titres ≥1:160 are more strongly associated with systemic rheumatic disease than lower titres, though the threshold for clinical significance depends on the pattern, specific antibody profile, and clinical context. A rising titre in serial testing may signal disease activity, while stable low titres in an asymptomatic individual usually require no intervention.

The fluorescence pattern seen on HEp-2 cells reflects the intracellular distribution of the target antigen. Homogeneous (diffuse) staining suggests anti-dsDNA or anti-histone antibodies; speckled patterns point to extractable nuclear antigens (Sm, RNP, Ro, La); nucleolar patterns to anti-RNA polymerase, Scl-70, or fibrillarin; and centromere pattern to anti-centromere antibodies. The pattern guides subsequent specific-antibody testing.

Each pattern narrows the differential diagnosis — homogeneous is classic for SLE and drug-induced lupus, speckled for SLE, Sjögren, and mixed connective-tissue disease, nucleolar for systemic sclerosis, and centromere for limited cutaneous systemic sclerosis. Pattern recognition is interpretive and operator-dependent, so modern practice couples IFA pattern with specific antibody identification.

Reflex testing identifies the molecular target of the ANA reactivity — anti-dsDNA, anti-Sm, anti-RNP, anti-Ro (SSA), anti-La (SSB), anti-Scl-70, anti-centromere, anti-Jo-1, and others. These antibodies have distinct disease associations and, in some cases, prognostic and therapeutic implications. Methods include enzyme immunoassay, multiplex bead assays, and line or dot blots.

Specific antibody identity is essential for classification and management — anti-dsDNA and anti-Sm are highly specific for SLE, anti-Ro and anti-La for Sjögren syndrome and neonatal lupus, anti-centromere for limited cutaneous systemic sclerosis, anti-Scl-70 for diffuse systemic sclerosis, and anti-Jo-1 for inflammatory myositis. The reflex cascade ensures that only positive ANA screens proceed to costly specific-antibody testing.